Nanoform, an innovative drug enabling nanotechnology company, has announced the construction of a GMP manufacturing plant to provide API ‘solution to particle’ nanonization for clinical trials.
Nanoform, a Helsinki, Finland-based drug particle engineering and nanotechnology company, is set to globalize its novel nanonization technology with the appointment of Christian Jones as Chief Commercial Officer.
Nanoform, an innovative drug particle engineering and nanotechnology company that provides novel API particle-size reduction services, is continuing its strategic growth through a significant €7 million investment, with Vator Securities acting as the sole bookrunner.